Research updates of RET proto-oncogene in non-small cell lung cancer
10.3760/cma.j.cn371439-20241115-00039
- VernacularTitle:RET原癌基因与非小细胞肺癌的研究现状
- Author:
Lei TANG
1
;
Zongyou CAI
;
Jianhua CHANG
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院深圳医院肿瘤内科，深圳 518116
- Keywords:
Proto-oncogene proteins c-ret;
Carcinoma, non-small-cell lung;
Molecular targeted therapy
- From:
Journal of International Oncology
2025;52(4):237-241
- CountryChina
- Language:Chinese
-
Abstract:
The RET protein encoded by RET proto-oncogene is a receptor tyrosine kinase that serves as a potential therapeutic target in non-small cell lung cancer (NSCLC) . In NSCLC, the incidence of RET fusions variants ranges from 1%-2% and is more common in younger, non-smoking patients. Traditional chemotherapy, immunotherapy, and multitarget kinase inhibitors have shown limited efficacy in treating RET fusion-positive NSCLC patients. However, selective RET inhibitors, such as selpercatinib and pralsetinib, have significantly improved the prognosis of those patients. The treatment strategy following resistance to selective RET inhibitors is a future research direction.
